RBC Capital analyst Gregory Renza maintained a Buy rating on Global Blood Therapeutics (NASDAQ:GBT) on Thursday, setting a price target of $75, which is approximately 52.47% above the present share price of $49.19.
Renza expects Global Blood Therapeutics to post earnings per share (EPS) of -$0.97 for the first quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Global Blood Therapeutics, with an average price target of $75.63.
The analysts price targets range from a high of $138 to a low of $45.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $36.89 million and a net profit of -$58.31 million. The company's market cap is $3.04 billion.
According to TipRanks.com, RBC Capital analyst Gregory Renza is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 19.0% and a 52.11% success rate.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.